medicina49巻11号

2012年11月発行

特集 いま，内科薬はこう使う 消化器薬

炎症性腸疾患治療薬：生物学的製剤

著者： 鎌田紀子¹ 渡辺憲治¹

所属機関： ¹大阪市立大学医学部消化器内科

ページ範囲：P.194 - P.196

　現在，わが国で承認されている抗TNFαモノクローナル抗体製剤について，その適応と使用方法などを述べる（表1）．

参考文献

1）Dignass A, et al：The second European evidence-based consensus on the diagnosis and management of Crohn's disease；Current management. J Crohns Colitis 4：28-62, 2010

2）Targan SR, et al：A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 337：1029-1036, 1997

3）Hanauer SB, et al：Human anti-necrosis factor monoclonal antibody（adalimumab）in Crohn's disease：the CLASSIC-1 trial. Gastroenterology 130：323-333, 2006

4）Hanauer SB, et al：Maintenance infliximab for Crohn's deisease：the ACCENT 1 randomized trial. Lancet 359：1541-1549, 2002

5）Colombel JF, et al：Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease：the CHARM trial. Gastroenterology 132：52-65, 2007

6）Kamm MA, et al：Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther 34：306-317, 2011

7）Sands BE, et al：Infliximab maintenance therap for fistulizing Crohn's disease. N Engl J Med 350：876-885, 2004

8）Reguiero M, et al：Infliximab prevents Crohn's disease reccurence after ileal resection. Gastroenterology 136：441-450, 2009

9）Sandborn WJ, Hananer SB：Infliximab in the treatment of Crohn's disease：A user's guide for clinician. Am J Gastroenterol 97：2962-2972, 2002

10）Colombel JF, et al：Infliximab, Azathioprine, or Combination therapy for Crohn's disease. N Engl J Med 362：1383-1395, 2010